Bone Fracture clinical trials

Explore recruiting bone fracture clinical trials.

Recruiting bone fracture studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Bone Fracture trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture - ILOBONE

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A multi-centre, single-arm study to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined ATMP) for bone healing in delayed union and non-union after long bone fractures (OrthoAlloUnion).

Spain, Italy, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM). Phase 3 pragmatic multicenter open labelled randomized trial.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer

Hungary, Spain, Italy, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Effects of a single denosumab injection on reduction of total contact cast treatment and consolidation of bone fractures caused by acute Charcot foot in patients with diabetes mellitus (CHARCOT study)

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Bone Fracture trials by city

Bone Fracture in Toronto Bone Fracture in Vancouver Bone Fracture in Montreal Bone Fracture in Calgary Bone Fracture in Edmonton Bone Fracture in Ottawa Bone Fracture in Winnipeg Bone Fracture in Quebec City Bone Fracture in Hamilton Bone Fracture in Kitchener Bone Fracture in London Bone Fracture in Halifax Bone Fracture in New York Bone Fracture in Los Angeles Bone Fracture in Chicago Bone Fracture in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease